The rise of bispecific antibodies for dual targeting, singular impact: technology and clinical advancements.

Bispecific antibodies (BsAbs) have emerged as a powerful therapeutic modality with the ability to simultaneously engage two distinct targets, enabling novel mechanisms of action that traditional monoclonal antibodies cannot achieve. This dual-targeting capability offers significant advantages in treating complex diseases such as cancer, autoimmune disorders, and infectious diseases by enhancing specificity, improving immune engagement, and reducing resistance mechanisms. The development of BsAbs has been driven by innovations in antibody engineering platforms, including BiTE, TriTAC, CrossMAb, XmAb, Fcab, and κλ-body technologies. These platforms allow the construction of diverse BsAb formats, ranging from compact single-chain variable fragments (scFvs) to full-length IgG-like molecules, each optimized for specific pharmacokinetic and pharmacodynamic profiles. Clinical candidates such as blinatumomab, HPN328, and XmAb14045 demonstrate the therapeutic potential and versatility of BsAbs, several of which have progressed to advanced stages of clinical trials or received regulatory approval. However, BsAb development poses unique challenges, including molecular heterogeneity, complex manufacturing processes, and the need for precise functional characterization. Emerging technologies such as high-resolution mass spectrometry, surface plasmon resonance (SPR), hydrogen‑deuterium exchange (HDX-MS), and AI-assisted modeling are increasingly being adopted to overcome these hurdles. As the field evolves, BsAbs are redefining therapeutic strategies by offering multi-functional approaches within a single molecule. Their ability to orchestrate complex biological interactions with high specificity positions them at the forefront of next-generation biologic. This article explores the technical advancements and clinical milestones that underscore the rising impact of BsAbs in modern medicine.